Biomarkers in cancer immunotherapy

Cancer Cell. 2015 Jan 12;27(1):12-4. doi: 10.1016/j.ccell.2014.12.004.


Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neoplasm / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / immunology*
  • Humans
  • Immunotherapy / methods
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • T-Lymphocytes / immunology


  • Antibodies, Neoplasm
  • Biomarkers, Tumor